Wakamoto PharmaceuticalWAKAMOTO PHARMACEUTICAL CO.,LTD.4512東証スタンダード医薬品FY ending Mar 2026, non-consolidated, J-GAAP
About 63% of Wakamoto Pharmaceutical's sales come from Ethical products business-related, with Otc products business-Related and Sales Development business-Related making up much of the rest.
It lost about ¥9 for every ¥100 of sales at the operating level.
Revenue changed -18.5% from the prior year.
FY ending Mar 2020 → FY ending Mar 2021
FY ending Mar 2020 → FY ending Mar 2021
For every ¥100 Wakamoto Pharmaceutical sells, how much goes where, and how much is kept.
Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.
Revenue by business segment, and the profit each one keeps.
※ Segment figures include inter-segment sales and do not sum to the company total
EDINET (FSA Japan)
有価証券報告書-第130期(2024/04/01-2025/03/31)
EDINET (FSA Japan)
有価証券報告書-第129期(2023/04/01-2024/03/31)
EDINET (FSA Japan)
有価証券報告書-第128期(2022/04/01-2023/03/31)
EDINET (FSA Japan)
有価証券報告書-第127期(令和3年4月1日-令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書-第126期(令和2年4月1日-令和3年3月31日)
Extracted from XBRL: 47 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.